INDOCO Indoco Remedies Q2 FY26 results (Jul–Sep 2025) and concall
Indoco Remedies reported a strong Q2 FY26 with consolidated revenue growth of 9.5% YoY and significant QoQ EBITDA margin expansion, signaling a turnaround from previous challenges. Regulatory progress was positive with a clean US FDA inspection of its API facility and tentative approval for Canagliflozin. While the company faces ongoing remediation costs and losses in subsidiaries, management is confident in future growth, debt reduction, and margin improvement through strategic focus on vertically integrated products and cost control.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
| Line item | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|
| Revenue | 411 | 390 | 440 | 485 |
| EBITDA | 12 | -1 | 18 | 43 |
| Net profit | -28 | -41 | -36 | -9 |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
